Colorectal cancer (CRC) is a common type of cancer, and at present the TNM staging system is the only tool in routine clinical use for predicting patient outcome and making treatment decisions. Nuclear expression of the metastasis associated protein S100A4 is a promising prognostic biomarker in CRC, and has been shown to identify a subset of TNM II patients with poor prognosis. This suggests that patients in TNM II which express nuclear S100A4 might benefit from adjuvant chemotherapy, which is usually given only to TNM III patients. In this project, we investigated the significance of S100A4 expression on sensitivity towards four commonly used chemotherapeutic drugs in CRC, 5-flourouracil (5FU), irinotecan (IRI), oxaliplatin (OXA) and cetuximab (CET). Two human CRC cell lines (HCT116 and SW620) were experimentally modified to express different levels of S100A4, and were exposed to increasing drug concentrations in 2D and 3D cultures. Cell viability assessed by the MTS assay was used as a screening tool, and some results were followed up using clonogenic survival and spheroid assays. HCT116 cells were generally more sensitive to the drugs than SW620 cells, while both cell lines were resistant to CET. S100A4 related differences in sensitivity were observed with the MTS assay in HCT116 treated with 5FU and SW620 treated with OXA, while there was no variation with IRI treatment. For OXA, the differences were observed at concentrations that are probably not relevant in cancer treatment in humans, whereas for 5FU the concentration range was probably relevant, but the differences could not be confirmed using other methods. In conclusion, S100A4 expression did not substantially influence in vitro sensitivity towards the drugs in the two investigated models. However, results from in vitro experiments cannot be directly translated into the clinic, and the relevance of S100A4 expression on drug sensitivity still warrants further investigations. An immunohistochemical study of S100A4 expression is ongoing in primary tumors from patients treated with adjuvant 5FU in a phase III trial. If S100A4 expression is associated with drug efficacy, additional in vitro studies will be necessary and the models systems established in this work may become useful.